Physician profile
John R Hunt
NPI 1578532537
$2,199.22
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $326 · 2022: $91.13 · 2023: $312 · 2024: $42.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.20 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $269.58 | 2019-2023 | |
| Amgen INC. | $147.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.46 | 2019-2023 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $123.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.92 | 2019 | |
| Lilly USA, LLC | $64.13 | 2019-2020 | |
| Dexcom, INC. | $56.51 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $49.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.44 | 2020-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $47.52 | 2023-2024 | Gvoke Hypopen |
| Abbvie INC. | $46.55 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $45.28 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $45.09 | 2019 | |
| Shire North American Group INC | $44.43 | 2019 | |
| Astellas Pharma US INC | $43.54 | 2019-2020 | |
| Radius Health, INC. | $41.31 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.51 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $27.91 | 2019-2020 | |
| Amarin Pharma, INC. | $25.47 | 2019-2020 | |
| Allergan, INC. | $24.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.70 | 2019 | |
| Abbott Laboratories | $22.86 | 2019 | |
| Axsome Therapeutics, INC. | $19.23 | 2023 | Auvelity |
| Sanofi Pasteur INC. | $19.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.73 | 2022 | |
| Phadia US INC. | $16.43 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.17 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $15.84 | 2020 | |
| Ironshore Pharmaceuticals INC. | $15.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2019 | |
| Gilead Sciences, INC. | $13.02 | 2020 | |
| Circassia INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.